Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDGE-Gastric: Combination Therapies in Advanced Upper Gastrointestinal Tract Malignancies
NCT05329766Phase 2Completed
- Sponsor
- Arcus Biosciences
- Start
- Jun 2022
- Primary completion
- Sep 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial of domvanalimab, zimberelimab and quemliclustat in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC) (7 arms), sponsored by Arcus Biosciences. Primary endpoints: Number of Participants with Adverse Events at 18 months and Objective Response Rate at 18 months. Started Jun 2022; status: completed.
02
Drugs
domvanalimabzimberelimabquemliclustat
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT05329766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05329766.